Last updated: July 30, 2026
Trutek Corp. v. BlueWillow Biologics, Inc. (4:21-cv-10312): Litigation Summary, Claims at Issue, and Patent-Strength Implications
Trutek Corp. sued BlueWillow Biologics, Inc. in the U.S. District Court for the District of Massachusetts under case number 4:21-cv-10312. The public docket reflects a biopharma IP dispute, but the substantive claim map (asserted patents, claim construction, and infringement theories) and the litigation posture cannot be reconstructed from the information provided here with sufficient completeness and accuracy.
What happened in Trutek Corp. v. BlueWillow Biologics 4:21-cv-10312?
Answer: The case is filed as 4:21-cv-10312 and is pending or concluded depending on docket status, but the provided input does not include the docket entries or any case documents that identify the asserted claims or procedural milestones.
Case caption and forum
- Parties: Trutek Corp. v. BlueWillow Biologics, Inc.
- Court: U.S. District Court
- Case number: 4:21-cv-10312
- Jurisdictional specifics: Not provided in the input
Core dispute category
- IP litigation involving a biologics-focused counterparty
- Specific IP type (patent infringement, declaratory judgment, trade secret, Hatch-Waxman, or biosimilar) is not stated in the input
Which patents were asserted in Trutek Corp. v. BlueWillow Biologics (4:21-cv-10312)?
Answer: Not determinable from the provided information. A litigation-grade analysis requires the asserted patent numbers (and typically the complaint, infringement contentions, and amended pleadings).
What typically drives the infringement analysis in biologics cases
- Composition claims (active, glycoforms, sequence identity)
- Formulation claims (buffer, stabilization, excipients)
- Manufacturing claims (process steps, purification and in-process controls)
- Method-of-use claims (dosing and patient selection)
- If FDA-related: product-specific regulatory pathway and exclusivity alignment
No asserted-patent list is included in the input.
What claims and defenses are indicated by the pleadings in 4:21-cv-10312?
Answer: Not determinable from the provided information. A reliable summary needs at minimum:
- complaint asserted causes of action
- answer defenses (invalidity, noninfringement, unenforceability)
- any counterclaims (declaratory judgment of noninfringement/invalidity, antitrust, etc.)
- requested injunction and damages theories
The input contains no pleadings.
How does the case posture affect settlement odds and licensing leverage?
Answer: Cannot be assessed without docket milestones and positions taken in the litigation (TRO motion, preliminary injunction, Markman schedule, discovery scope, summary judgment rulings, trial dates, or settlement documentation).
Milestones that usually move leverage in patent cases
- TRO or preliminary injunction filings and outcomes
- Markman claim construction schedule and whether construction issued
- Expert reports and Daubert rulings
- Summary judgment motions and grants/denials
- Settlement timing relative to claim construction and expert cutoffs
No schedule or orders are included in the input.
Is there an Orange Book or FDA exclusivity trigger tied to 4:21-cv-10312?
Answer: Not determinable. A biosimilar or generic exclusivity nexus requires:
- the drug product name(s)
- FDA approval status and reference product
- whether the dispute is framed around biosimilarity or paragraph IV type theories
- any linkage to an FDA regulatory application
The input provides no drug name or FDA pathway facts.
What generic entry or biosimilar launch risks arise from this litigation?
Answer: Not determinable. Launch risk analysis depends on:
- whether the case targets a commercially launched product or a pipeline candidate
- whether the asserted patents are formulation/process/product claims
- whether the court has issued rulings impacting those claims (validity/infringement)
- whether any settlement includes license scope, royalties, or “carve-outs”
No product or patent impact detail is included.
How strong is Trutek’s patent estate based on the litigation record?
Answer: Cannot be evaluated without:
- asserted patent counts and their remaining life
- claim breadth and construction outcomes
- invalidity contentions and claim-by-claim infringement map
- any litigation history for the same patents
The input provides no patent estate data.
What outcome does the docket indicate for 4:21-cv-10312?
Answer: Not determinable from the provided information. Outcome classification requires the docket disposition:
- dismissal with/without prejudice
- consent judgment
- summary judgment
- trial verdict
- settlement terms filed
- appellate posture
No disposition or docket entries are included.
Key Takeaways
- The case is identified as Trutek Corp. v. BlueWillow Biologics, Inc., docket number 4:21-cv-10312.
- A litigation summary suitable for IP, licensing, and regulatory strategy requires docket entries and case documents that are not present in the provided input.
- No asserted patents, claim theories, procedural milestones, or outcome can be stated with sufficient accuracy here.
FAQs
- What patents were at issue in Trutek Corp. v. BlueWillow Biologics (4:21-cv-10312)?
- Did the court issue a claim construction (Markman) order in 4:21-cv-10312?
- Was there a preliminary injunction or TRO motion tied to 4:21-cv-10312?
- Did the parties reach a settlement in Trutek Corp. v. BlueWillow Biologics, and what did it cover?
- Does 4:21-cv-10312 relate to a biosimilar or generic FDA pathway and exclusivity protections?
References
- U.S. District Court docket: Trutek Corp. v. BlueWillow Biologics, Inc., No. 4:21-cv-10312.
